Evotec SE completed the acquisition of Central Glass Germany GmbH from Central Glass Co., Ltd..
November 01, 2022
Share
Evotec SE (XTRA:EVT) agreed to acquire Central Glass Germany GmbH from Central Glass Co., Ltd. (TSE:4044) for €1 on August 24, 2022. Central Glass Germany has reported Revenue of €9.097 million, total assets of €10.077 million and total common equity of €3.798 million during Fiscal year ending December 2021. The Board resolution date is August 24, 2022. The transaction is expected to complete on November 1, 2022. Shigeo Yamaguchi, Eberhard, Mauritz von Einem, Hendrik von Mellenthin, Ulrich Lienhard, Friedrich Gebert, Marcus Nothhelfer, Tobias Neufeld, Johannes Landry, Dimitrios Christopoulos, Deniz Günal, Jens Knipping, Miho Kuramochi, Julia Regenauer of ARQIS Rechtsanwälte acted as legal advisor to Central Glass Co., Ltd. goetzpartners securities Limited acted as financial advisor to Evotec SE. Markus Schmal, Jan Knorr and Jan Knorr of Ebner Stolz Gmbh & Co. Kg acted as financial due diligence provider to Evotec SE.
Evotec SE (XTRA:EVT) completed the acquisition of Central Glass Germany GmbH from Central Glass Co., Ltd. (TSE:4044) on November 1, 2022. Central Glass Germany GmbH was renamed to Evotec Drug Substance (Germany) GmbH (“Evotec DS”) and continues to operate under this name.
Central Glass Co.,Ltd. is a Japan-based company mainly engaged in manufacturing and sales of glass products and chemical products. The Company operates in two segments. The Glass Products segment is engaged in manufacturing and sales of building glass, automobile glass and glass for electronic materials. The Chemical Products segment is engaged in manufacturing and sales of chemicals, fine chemicals, fertilizers, glass fibers. The Company mainly operates in Japan, North Americas and other areas.
CENTRAL GLASS CO., LTD. 
